New Research Provides Support For Continued PSA Screening In Men With Specific Genetic Mutations.
BBC News (9/10) reports, "PSA screening has been contentious in the past because of concerns about over-diagnosis," and the medical community also remains at odds about "how effective it was at reducing mortality." Aiming to clarify the issue, UK scientists set about analyzing preliminary data culled from the "first large international prostate cancer screening study," which is "targeted at men with a known genetic predisposition to the disease." Investigators eventually concluded that "it appears that PSA screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition." In other words, their work "provides support for continued screening in men with genetic mutations." Reuters (9/10, Kelland) also covers the study.
George M. Suarez, M.D.
Dr. George M. Suarez is the co-founder and Medical Director, Emeritus of USHIFU and International HIFU. Dr. Suarez has served on the Board of Directors of Focus Surgery, the manufacturer of the Sonoblate 500. He has performed more HIFU procedures than any single urologist in North America, and has trained the vast majority of urologists performing HIFU. For additional information on HIFU and on Dr. George M. Suarez, please visit www.hifumedicalexpert.com
No comments:
Post a Comment